forthcoming

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Dynamic Rewards Unleashed

Source Node:
Time Stamp: June 1, 2023 1:06 PM - Modified On: June 1, 2023 - Published By:
Source Cluster:
Republished By Plato

Following weeks of preparation and hard work, we’re incredibly excited to open the Paribus Mainnet v1 tomorrow. This marks the welcome return of our protocol and heralds the beginning of our rewards program. For those who participated in our staking program, the concept behind the rewards program will be simple to understand. We’ve allocated 100 million PBX tokens to be issued as rewards to borrowers on the platform. This concept is even more exciting because the rewards are scheduled to be released evenly across every block and are anticipated to

Welcome to Half BAYCD

Source Node:
Time Stamp: August 30, 2022 2:37 PM - Modified On: August 30, 2022 - Published By:
Source Cluster:
Republished By Plato

Author: Half BAYCD The future of Web3 cannabis One of the greatest hurdles in the Web3 space is creating opportunities without creating violations; we set out to bring ownership of a cannabis company to our holders and we were determined to do it in a way that didn’t bring forth securities violations and ensure longevity and sustainability are our primary focus. We’ve created Half BAYCD as an opportunity for our pass holders to either license their own BAYC/MAYC/BAKC/Koda or partner with a holder and do a revenue share on the